reviparin trial summary

All type of patients: 1 trials - CREATE

No demonstrated result

suggested reinfarction by 24% (not demonstrated)

suggested death at 30 days by 13% (not demonstrated)

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

All type of patients: 1 trials - REDUCE

No demonstrated result

suggested MACE by 52% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Unplanned revascularisation for ischaemia	no data
death, MI, unplanned revascularization	no data
myocardial infarction (fatal and non fatal)	no data
MACE	0.48 [0.24 0.97]	p=0.04	0	612	1	REDUCE,
All cause death	no data
Minor bleeding	no data
Bleeding	0.88 [0.31 2.44]	p=1.00	0	612	1	REDUCE,
Major bleeding	no data
net benefit	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
symptomatic venous thromboembolism at the end of treatment	0.96 [0.27 3.41]	p=1.00	0	271	1	COLOMBUS sub group,
recurrent symptomatic venous thromboembolism and death at the end of treatment	no data
Recurrent Symptomatic Venous Thromboembolism or death	no data
fatal pulmonary embolism	no data
All cause death	no data
Minor bleeding	no data
Major bleeding	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Arthroscopy: 1 trials - Wirth

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	0.21 [0.02 1.81]	p=1.00	0	239	1	Wirth,
Symptomatic venous thromboembolism (DVT, PE)	0.15 [0.01 2.92]	p=1.00	0	239	1	Wirth,
total VTE and all-cause mortality	no data
major or clinically relevant non-major bleeding	no data
Minor bleeding	3.13 [0.32 30.51]	p=1.00	0	239	1	Wirth,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

General surgery: 1 trials - Kakkar

No demonstrated result

suggested Bleeding by 31% (not demonstrated)

suggested Major bleeding by 69% (not demonstrated)

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Symptomatic pulmonary embolism	0.34 [0.03 3.25]	p=1.00	0	1351	1	Kakkar,
asymptomatic DVT	1.10 [0.65 1.86]	p=1.00	0	1311	1	Kakkar,
Symptomatic venous thromboembolism (DVT, PE)	no data
wound haematoma / infection	0.56 [0.35 0.90]	p=0.04	0	1351	1	Kakkar,
transfusion	no data
All cause death	0.61 [0.14 2.55]	p=1.00	0	1351	1	Kakkar,
Bleeding	0.69 [0.48 1.00]	p=0.04	0	1351	1	Kakkar,
Major bleeding	0.31 [0.10 0.96]	p=0.04	0	1351	1	Kakkar,

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Patients with immobilization of the lower extremities: 1 trials - Lassen

No demonstrated result

Endpoint	TE [95% CI]	p val	I2	n	k	trials
Venous thromboembolism	0.50 [0.27 0.93]	p=0.04	0	371	1	Lassen,
Symptomatic venous thromboembolism (DVT, PE)	0.08 [0.00 1.40]	p=1.00	0	438	1	Lassen,
total VTE and all-cause mortality	no data
major or clinically relevant non-major bleeding	no data
Minor bleeding	no data

TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients

Reviparin antithrombotics